Clovis S Palmer1, Matias Ostrowski, Maelenn Gouillou, Louis Tsai, Di Yu, Jingling Zhou, Darren C Henstridge, Anna Maisa, Anna C Hearps, Sharon R Lewin, Alan Landay, Anthony Jaworowski, Joseph M McCune, Suzanne M Crowe. 1. aCentre for Biomedical Research, Burnet Institute, Melbourne, Australia bInstituto de Investigaciones Biomédicas en Retrovirus y SIDA. Facultad de Medicina, Buenos Aires, Argentina cCentre for Population Health, Burnet Institute, Melbourne dLaboratory of Molecular Immunomodulation, School of Biomedical Sciences, Monash University, Clayton eCellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute fDepartment of Infectious Diseases, Monash University gInfectious Diseases Department, The Alfred hospital, Melbourne, Australia hDepartment of Immunology/Microbiology, Rush University Medical Center, Chicago, Illinois iDivision of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Abstract
OBJECTIVES: Glucose metabolism plays a fundamental role in supporting the growth, proliferation and effector functions of T cells. We investigated the impact of HIV infection on key processes that regulate glucose uptake and metabolism in primary CD4 and CD8 T cells. DESIGN AND METHODS: Thirty-eight HIV-infected treatment-naive, 35 HIV+/combination antiretroviral therapy, seven HIV+ long-term nonprogressors and 25 HIV control individuals were studied. Basal markers of glycolysis [e.g. glucose transporter-1 (Glut1) expression, glucose uptake, intracellular glucose-6-phosphate, and L-lactate] were measured in T cells. The cellular markers of immune activation, CD38 and HLA-DR, were measured by flow cytometry. RESULTS: The surface expression of the Glut1 is up-regulated in CD4 T cells in HIV-infected patients compared with uninfected controls. The percentage of circulating CD4Glut1 T cells was significantly increased in HIV-infected patients and was not restored to normal levels following combination antiretroviral therapy. Basal markers of glycolysis were significantly higher in CD4Glut1 T cells compared to CD4Glut1 T cells. The proportion of CD4Glut1 T cells correlated positively with the expression of the cellular activation marker, HLA-DR, on total CD4 T cells, but inversely with the absolute CD4 T-cell count irrespective of HIV treatment status. CONCLUSION: Our data suggest that Glut1 is a potentially novel and functional marker of CD4 T-cell activation during HIV infection. In addition, Glut1 expression on CD4 T cells may be exploited as a prognostic marker for CD4 T-cell loss during HIV disease progression.
OBJECTIVES:Glucose metabolism plays a fundamental role in supporting the growth, proliferation and effector functions of T cells. We investigated the impact of HIV infection on key processes that regulate glucose uptake and metabolism in primary CD4 and CD8 T cells. DESIGN AND METHODS: Thirty-eight HIV-infected treatment-naive, 35 HIV+/combination antiretroviral therapy, seven HIV+ long-term nonprogressors and 25 HIV control individuals were studied. Basal markers of glycolysis [e.g. glucose transporter-1 (Glut1) expression, glucose uptake, intracellular glucose-6-phosphate, and L-lactate] were measured in T cells. The cellular markers of immune activation, CD38 and HLA-DR, were measured by flow cytometry. RESULTS: The surface expression of the Glut1 is up-regulated in CD4 T cells in HIV-infectedpatients compared with uninfected controls. The percentage of circulating CD4Glut1 T cells was significantly increased in HIV-infectedpatients and was not restored to normal levels following combination antiretroviral therapy. Basal markers of glycolysis were significantly higher in CD4Glut1 T cells compared to CD4Glut1 T cells. The proportion of CD4Glut1 T cells correlated positively with the expression of the cellular activation marker, HLA-DR, on total CD4 T cells, but inversely with the absolute CD4 T-cell count irrespective of HIV treatment status. CONCLUSION: Our data suggest that Glut1 is a potentially novel and functional marker of CD4 T-cell activation during HIV infection. In addition, Glut1 expression on CD4 T cells may be exploited as a prognostic marker for CD4 T-cell loss during HIV disease progression.
Authors: Ferdinando Nicoletti; Paolo Fagone; PierLuigi Meroni; James McCubrey; Klaus Bendtzen Journal: Drug Discov Today Date: 2011-05-23 Impact factor: 7.851
Authors: Ryan D Michalek; Valerie A Gerriets; Sarah R Jacobs; Andrew N Macintyre; Nancie J MacIver; Emily F Mason; Sarah A Sullivan; Amanda G Nichols; Jeffrey C Rathmell Journal: J Immunol Date: 2011-02-11 Impact factor: 5.422
Authors: Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Lorrie Epling; Juli Teague; Mark A Jacobson; Russell P Tracy; Lawrence Corey; Steven G Deeks Journal: J Infect Dis Date: 2011-05-15 Impact factor: 5.226
Authors: Peter W Hunt; Alan L Landay; Elizabeth Sinclair; Jeffrey A Martinson; Hiroyu Hatano; Brinda Emu; Philip J Norris; Michael P Busch; Jeffrey N Martin; Cicely Brooks; Joseph M McCune; Steven G Deeks Journal: PLoS One Date: 2011-01-31 Impact factor: 3.240
Authors: Clovis S Palmer; Joshua J Anzinger; Tiffany R Butterfield; Joseph M McCune; Suzanne M Crowe Journal: J Vis Exp Date: 2016-08-12 Impact factor: 1.355
Authors: Greg S Gojanovich; Cecilia M Shikuma; Cris Milne; Daniel E Libutti; Dominic C Chow; Mariana Gerschenson Journal: AIDS Res Hum Retroviruses Date: 2019-09-17 Impact factor: 2.205
Authors: Greg S Gojanovich; Denise L Jacobson; Jennifer Jao; Jonathan S Russell; Russell B Van Dyke; Daniel E Libutti; Tanvi S Sharma; Mitchell E Geffner; Mariana Gerschenson Journal: AIDS Res Hum Retroviruses Date: 2020-07-20 Impact factor: 2.205
Authors: Lance M Villeneuve; Phillip R Purnell; Kelly L Stauch; Shannon E Callen; Shilpa J Buch; Howard S Fox Journal: J Neurovirol Date: 2016-02-03 Impact factor: 2.643